| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
80,420,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Verve Therapeutics is a genetic medicines company developing an approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Co.'s primary product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver. PCSK9 is a validated target that plays a critical role in controlling blood low-density lipoprotein cholesterol through its regulation of the low-density lipoprotein receptor. Co.'s second program is designed to turn off the ANGPTL3 gene in the liver. ANGPTL3 is a main regulator of cholesterol and triglyceride metabolism.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
1,800,000 |
1,800,000 |
1,810,000 |
| Total Buy Value |
$0 |
$18,000,000 |
$18,000,000 |
$18,121,526 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
2 |
| Total Shares Sold |
1,514 |
2,068 |
2,068 |
1,570,794 |
| Total Sell Value |
$12,475 |
$18,818 |
$18,818 |
$35,262,071 |
| Total People Sold |
1 |
2 |
2 |
7 |
| Total Sell Transactions |
1 |
2 |
2 |
35 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fmr Corp |
See Remark 1 |
– – • |
2022-07-01 |
4 |
S |
$15.66 |
$607,217 |
I/I |
(38,775) |
773,729 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – • |
2022-06-30 |
4 |
S |
$15.21 |
$286,100 |
I/I |
(18,810) |
772,504 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – • |
2022-06-29 |
4 |
S |
$15.50 |
$536,376 |
I/I |
(34,409) |
791,314 |
|
- |
|
| Adelman Burt A |
Director |
– • – |
2022-05-12 |
4 |
B |
$12.15 |
$121,526 |
I/I |
10,000 |
18,700 |
2.1 |
- |
|
| Kathiresan Sekar |
Chief Executive Officer |
• • – |
2022-03-18 |
4 |
OE |
$2.87 |
$199,964 |
D/D |
69,674 |
477,525 |
|
- |
|
| Adelman Burt A |
Director |
– • – |
2022-03-15 |
4 |
B |
$21.38 |
$85,535 |
I/I |
4,000 |
8,700 |
2.1 |
- |
|
| Fmr Corp |
See Remark 1 |
– – • |
2022-03-09 |
4 |
S |
$29.01 |
$115,199 |
I/I |
(3,971) |
825,723 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – • |
2022-02-09 |
4 |
S |
$29.46 |
$388,577 |
I/I |
(13,190) |
829,694 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – • |
2022-02-01 |
4 |
S |
$29.04 |
$1,033,069 |
I/I |
(35,574) |
842,884 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – • |
2022-01-27 |
4 |
S |
$29.26 |
$263,030 |
I/I |
(8,983) |
878,458 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – • |
2022-01-26 |
4 |
S |
$29.67 |
$4,680,389 |
I/I |
(149,853) |
887,441 |
|
- |
|
| Kathiresan Sekar |
Chief Executive Officer |
• • – |
2022-01-04 |
4 |
AS |
$39.90 |
$74,613 |
D/D |
(1,870) |
406,536 |
|
- |
|
| Kathiresan Sekar |
Chief Executive Officer |
• • – |
2022-01-04 |
4 |
OE |
$1.39 |
$2,599 |
D/D |
1,870 |
408,406 |
|
- |
|
| Kathiresan Sekar |
Chief Executive Officer |
• • – |
2021-12-28 |
4 |
AS |
$39.90 |
$267,051 |
D/D |
(6,693) |
406,536 |
|
- |
|
| Kathiresan Sekar |
Chief Executive Officer |
• • – |
2021-12-28 |
4 |
OE |
$1.39 |
$9,303 |
D/D |
6,693 |
413,229 |
|
- |
|
| Kathiresan Sekar |
Chief Executive Officer |
• • – |
2021-12-27 |
4 |
AS |
$40.02 |
$1,688,484 |
D/D |
(42,000) |
406,536 |
|
- |
|
| Kathiresan Sekar |
Chief Executive Officer |
• • – |
2021-12-27 |
4 |
OE |
$1.39 |
$58,380 |
D/D |
42,000 |
448,536 |
|
- |
|
| Fmr Corp |
10% Owner |
– – • |
2021-12-23 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,037,294 |
|
- |
|
| Kathiresan Sekar |
Chief Executive Officer |
• • – |
2021-12-23 |
4 |
AS |
$39.90 |
$2,274,300 |
D/D |
(57,000) |
406,536 |
|
- |
|
| Kathiresan Sekar |
Chief Executive Officer |
• • – |
2021-12-23 |
4 |
OE |
$1.39 |
$79,230 |
D/D |
57,000 |
463,536 |
|
- |
|
| Kathiresan Sekar |
Chief Executive Officer |
• • – |
2021-12-22 |
4 |
AS |
$37.38 |
$2,206,304 |
D/D |
(57,000) |
406,536 |
|
- |
|
| Kathiresan Sekar |
Chief Executive Officer |
• • – |
2021-12-22 |
4 |
OE |
$1.39 |
$79,230 |
D/D |
57,000 |
463,536 |
|
- |
|
| Bellinger Andrew |
Chief Scientific Officer |
• – – |
2021-12-22 |
4 |
AS |
$37.42 |
$580,469 |
D/D |
(15,000) |
5,000 |
|
- |
|
| Bellinger Andrew |
Chief Scientific Officer |
• – – |
2021-12-22 |
4 |
OE |
$1.48 |
$22,200 |
D/D |
15,000 |
20,000 |
|
- |
|
| Ashe Andrew D. |
See Remarks |
• – – |
2021-12-02 |
4 |
B |
$32.10 |
$128,420 |
D/D |
4,000 |
170,722 |
2.74 |
- |
|
50 Records found
|
|
Page 1 of 2 |
|
|
